Personalis Inc

PSNL remains in a Stage 2 advancing uptrend with clear higher highs and lows, and price is holding above the rising 9 and 21 EMAs after a modest pullback. The medium-term bias is bullish under the momentum + EPS framework, but extreme overbought readings warrant patience. Favor continuation participation on shallow pullbacks into the EMA support zone.

• ↑Operates in a $20B MRD testing market with unique ultra-sensitive detection.
• ↑Clinical test volume rose 26% sequentially and 364% year-over-year.
• ↓Q1 net loss of $30M vs. $15.8M YoY highlights heavy cash burn.